The Cell and Gene Therapy Catapult executive team manage the organisation on a day-to-day basis.
Chief Executive Officer
Dedicated to building a Cell and Gene Therapy industry in the UK, Keith has built a team of over 180 cell and gene therapy experts in state-of-the-art laboratories in London and a unique large-scale manufacturing centre in Stevenage.
Keith established the Cell and Gene Therapy Catapult in 2012. Prior to this he was Director of the Scottish National Blood Transfusion Service, focused on modernising the blood supply from vein-to-vein and expanding into cell therapy. Keith has held various positions in Biotechnology companies, he was Managing Director of Bioscot, one of Scotland’s first Biotechnology companies; at NASDAQ listed Serologicals he was Vice President of Diagnostics Operations, then Vice President of Global Manufacturing. He is currently a Director of the UK Bio Industry Association, a Director Of the Alliance for Regenerative Medicine and serves on the ISCT Strategic Advisory Council. He has been Chairman of the UK Blood Forum, a Director of the European Blood Alliance and Treasurer of the International Plasma Fractionators Association. In 1993, when at Bioscot, he received the Queen’s Award for export.
Keith holds first and second degrees in Biological Sciences and Applied Genetics from Birmingham University along with an MBA from Edinburgh University.
Chief Business Officer
Part of the team that created the Catapult, he is also an Executive Director. He is responsible for strategy, and finding, funding and transacting the business of the Catapult.
He has been a champion of the early integration of healthcare economics and reimbursement expertise into decision- making and clinical product design in the sector. He began his career in international investment banking and has successfully managed a number of biotechnology SMEs. His first degree was from Oxford University in Biology and he has an MBA (High Honors) from Chicago Booth. He is a non-executive director of an immune-oncology company and periodically assists the UK Government and international organisations in the development of initiatives in healthcare innovation.
Dr Jacqueline Barry
Chief Clinical Officer
Jacqueline joined Cell and Gene Therapy Catapult as Director of Regulatory Affairs and has since been promoted to Chief Clinical Officer.
Prior to this Jacqueline worked at the Scottish National Blood Transfusion Service in a number of senior regulatory and quality positions, the responsibility for which included designing the regulatory strategy for the Cellular Therapies developed by the Blood Transfusion Service, acting as Responsible Person for Blood and Qualified Person for medicinal product release. Before that she held a number of post-Doctoral academic posts at the University of Edinburgh studying neuromuscular regeneration. She has considerable experience in the development, translation, clinical trial and approval of cell based medicinal products and therapies.
Dr Stephen Ward
Chief Manufacturing Officer
Prior to becoming the new Chief Manufacturing Officer of the Cell and Gene Therapy Catapult Stephen has established the world-class industrialisation capabilities at both the Guy’s Hospital facilities in London, plus designed and built the innovative GMP manufacturing centre in Stevenage.
As the first Chief Operating Officer of CGT Catapult Stephen brings over 25 years of biological medicine research, development and manufacturing experience to the organisation. Stephen enjoys bringing high impact therapies to patients, by developing commercially viable products. Stephen is passionate about securing and growing the cell and gene therapy manufacturing and development supply chain.
He is the current Chair of the BIA’s Manufacturing Advisory Committee, actively promoting and supporting UK biomanufacturing at Government as well as grass root level. His first degree was from the University of Birmingham, and his second degree from the Medical School of Southampton University.
Dr Jonathan Appleby
Chief Scientific Officer
Dr Appleby joined CGT Catapult as Chief Scientific Officer in October 2018. Prior to joining he was CSO for Cell and Gene Therapy at GSK’s Rare Diseases Unit where he also led the team that developed and launched Strimvelis, the multi-award winning and first autologous stem cell gene therapy to be approved for commercial use.
Dr Appleby has worked in all phases of medicines development from discovery to launch and brings decades of industry experience in both conventional and ATMP medicines development. Prior to joining GSK’s Rare Diseases Unit, Dr Appleby was Director and Portfolio Manager at the GSK Centre of Excellence for External Drug Development. In this role, he discovered, in-licensed and developed new technologies and assets with SME companies across a broad range of therapeutic areas. Dr Appleby graduated from the University of Leeds with an honours degree in Genetics and a PhD from the Department of Biochemistry and Molecular Biology.
Interim Chief Financial Officer
Stephen was appointed as Interim Chief Finance Officer of the Cell and Gene Therapy Catapult in July 2018.
Stephen is a Chartered Management Accountant and has broad experience from several industries including Telecoms, IT and Insurance working in SMEs, Multinational and International corporations. He was the Interim CFO of Prudential PGDS and has participated in the successful divestment and IPO with Direct Line Group Plc and held senior management roles in Motorola, AOL, and the startup 3, part of the Hutchison Whampoa Group. His experience has covered all aspects of finance including financial planning and strategy, decision support, manufacturing/distribution, IT systems implementations and HR. Stephen has an MBA from the University of Leicester.
Manufacturing Centre Director
James was appointed Manufacturing Centre Director of the Cell and Gene Therapy Catapult in March 2016. Working closely with his Quality colleagues he has day to day responsibility for all operational activities within the Manufacturing Centre.
This encompasses managing the support network required by the multiple collaborator teams to produce their products within the segregated modules. In addition, he plays a strategic role developing the supply chain cluster around the Centre as well as securing its future sustainability. James has over 20 years production and operations management experience within the UK life sciences industry having previously worked for therapeutic monoclonal antibody contract manufacturers and a number of other biotech & service companies. James has been involved in the process development, manufacture, cryo-storage and distribution of numerous biological products.
Jon Halling was appointed Quality Director of the Cell and Gene Therapy Catapult in April 2016. He has responsibility for the company quality management system.
This includes all quality assurance related activity which ensures the GMP facility and support services are maintained in strict compliance with the governing regulations, assuring our collaborators that their manufacturing environment is maintained fit for purpose. Jon also has responsibility for the Centre’s quality control service provision which includes raw materials, environmental monitoring, microbiology, in-process and final product testing services.
Jon has over 20 years’ GMP quality experience in regulated pharma and biopharma manufacturing environments including working with diagnostic enzymes, monoclonal antibodies, therapeutic proteins and attenuated viral vaccines for both contract manufacturers and internal innovators.
Dr Michael Bennet
Director of Business Development
Michael is Director of Business Development at Cell and Gene Therapy Catapult, managing the business development, intellectual property and legal teams.
Michael is an experienced negotiator who has closed tens of multi-million US dollar revenue generating agreements such as in and out licences and settlement agreements. Previously Michael has held a number of executive management positions and was the Vice President of Business Development and Licensing for Oxford Gene Technology Ltd, Vice President of Sales and Marketing for Molecular Sensing Plc, Market Manager for Roche Diagnostics and Product Manager for Hybaid after spending four years as a post-doctoral researcher at the University of Bristol and the Royal Free Hospital in London.
He is a chartered biologist (CBiol) holds a BSc (Hons) in Biology from the University of Paisley along with a doctorate (D.Phil) from the University of Oxford.
Dr Damian Marshall
Director of Industrialisation, new and enabling technologies
Damian leads the assay development and validation team which underpins a diverse portfolio of cell therapy products at various stages of clinical maturity from pre-FiM to phase II.
Damian has over 15 years of assay development experience in the cell therapy and life sciences fields having previously managed the R&D portfolios for both SMEs and LGC Ltd and has successfully managed a European life sciences business with an annual turnover in excess of £15million.
Damian graduated with a degree in biological sciences and a PhD in developmental biology from Manchester University.
Director of Industrialisation, Manufacturing
Julie has more than 20 years’ experience across large pharma, biotech and academic laboratories, including 7 years at Pfizer Ltd as Biology Lead for a cell replacement therapy for Age Related Macular Degeneration which achieved First-in-Human in 2015.
Working closely with our collaborators she is responsible for the development and technical transfer of cell and gene therapy manufacturing processes ensuring they meet quality and regulatory requirements. Julie holds a BSc. Hons degree in Biology from the University of Southampton